At a glance
- Originator Whitby Pharmaceuticals
- Class Antiparkinsonians; Neuroprotectants
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 22 Jun 2001 No-Development-Reported for Parkinson's disease in USA (Unknown route)